Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Being part of an etf should increase the number of buys. Both in creating the etf and curious people looking at the companies in it.
I'll be at a ceremony on Tuesday when we hey the news. I don't want to be rode and keep checking my phone :(
Actually four pictures, you forgot the most important, the beach
I'll make some time to check it out now. Just moved and unpacking boxes isn't fun.
Pharmacyte Biotech Inc (OTCMKTS:PMCB): Why It’s Up, And What We’re Looking For Next
https://www.insiderfinancial.com/pharmacyte-biotech-inc-otcmktspmcb-why-its-up-and-what-were-looking-for-next/118805/
Pharmacyte Biotech Inc (OTCMKTS:PMCB) just put out a press release detailing some research conducted in Chicago, and the company has picked up an 11% boost on the release. The research doesn’t relate directly to PharmaCyte, but it does highlight a potential impact that its pipeline assets may have in a currently very under-served arena of oncology, and it’s this potential that is driving the gains.
As more investigation into the hypothesis derived from the data rolls out, there’s a chance that PharmaCyte could gain further strength. We know it’s responsive to this sort of release now, and with more research expected, there’s potential there – assuming the forward data supports the current hypothesis.
So, what’s the research, how does it apply to PharmaCyte, and what are we watching going forward?
The release detailed research performed at the Ann and Robert H. Lurie Children’s Hospital of Chicago and Northwestern University’s Feinberg School of Medicine, and subsequently published in a journal called Child’s Nervous System. The article in the journal was titled:
“Spontaneous involution of pediatric low-grade gliomas: high expression of cannabinoid receptor 1 (CNR1) at the time of diagnosis may indicate involvement of the endocannabinoid system”
Now, that sounds pretty technical right off the bat, but it’s not overly complicated when broken down. Basically, it’s saying that lots of endocannabinoid action (as measured by the level of a receptor associated with cannabinoids) seems to contribute to the shrinking of brain tumors (the most common type) in children.
Broken down a little further, the hypothesis (as outlined in the above title) points to the shrinking of what are called pediatric low-grade gliomas (P-LGG). The standard of care therapy on these P-LGGs is to surgically remove them. Sometimes (and surprisingly often) the tumors shrink considerably after they’ve been operated on, but not fully removed. We don’t know why, but the research suggests it’s something to do with the cannabinoid system in humans being a sort of built in cancer defense mechanism.
How did the research come to this conclusion? Because in all of the children that experienced post-surgical tumor shrinkage, there was a very high level of CNR1 at diagnosis.
The extension is, then, that treatments which employ cannabinoids to fight tumors are a sort of amplification of the body’s natural defense. PharmaCyte is developing one such treatment by way of its lead asset – a technology called Cell in a Box for which it picked up a license from a (primarily) CMO called Austrianova – and that’s why the company is gaining strength on the journal publication.
We’ve covered PharmaCyte’s technology on a number of occasions, so readers looking for some detail can find it here. By way of a brief introduction, however, it’s a chemo drug that can be injected and activated close to a target tumor, greatly increasing selectivity in the cells it targets, and by proxy, reducing toxicity associated with treatment. Put simply, it’s a chemotherapy drug without the side effects. This is a chemo agent, of course, and has nothing to do with cannabinoids. In it’s brain cancer target, however, the company is using a cannabinoid derived substance as the active drug. This is where it ties in to the research linking cannabinoids and brain tumor shrinkage in children.
So, what are we looking for as an upside driver going forward?
It’s important to say that this isn’t research directly related to a PharmaCyte asset, in that none of PharmaCyte’s treatments were used to induce any sort of tumor shrinkage, or anything like that. While that’s important, however, we don’t think it’s limiting in terms of how far PharmaCyte can run if forward data reinforces the original hypothesis. Naturally, then, this is what we’re looking for – a reinforcing of the potential of the company’s cannabinoid asset, as inferred by data supporting the tumor shrinking capability of cannabinoids.
Checking the Charts for Pharmacyte Biotech Inc. (PMCB)
http://yankeeanalysts.com/2016/12/28/checking-the-charts-for-pharmacyte-biotech-inc-pmcb/
In terms of Relative Strength Index for Pharmacyte Biotech Inc. (PMCB), the 14-day RSI is currently noted at 66.79, the 7-day is 63.54, and the 3-day is sitting at 62.8. The Relative Strength Index (RSI) is a very popular momentum indicator used for technical analysis. The RSI can help show whether the bulls or the bears are currently strongest in the market. The RSI may be used to help spot points of reversals more accurately. The RSI was developed by J. Welles Wilder. As a general rule, an RSI reading over 70 would signal overbought conditions. A reading under 30 would indicate oversold conditions. As always, the values may need to be adjusted based on the specific stock and market. RSI can also be a valuable tool for trying to spot larger market turns.
Let’s check on another technical indicator. At the time of writing, the 14-day ADX for Pharmacyte Biotech Inc. (PMCB) is 51.11. Many technical chart analysts believe that an ADX reading over 25 would suggest a strong trend. A level under 20 would indicate no trend, and a reading from 20-25 would suggest that there is no clear trend signal. The ADX is typically plotted along with two other directional movement indicator lines, the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI). Some analysts believe that the ADX is one of the best trend strength indicators available.
Investors may be studying other technical indicators like the Williams Percent Range or Williams %R. The Williams %R is a momentum indicator that helps measure oversold and overbought levels. This indicator compares the closing price of a stock in relation to the highs and lows over a certain time period. A common look back period is 14 days. Pharmacyte Biotech Inc. (PMCB)’s Williams %R presently stands at -28.75. The Williams %R oscillates in a range from 0 to -100. A reading between 0 and -20 would indicate an overbought situation. A reading from -80 to -100 would indicate an oversold situation.
In terms of CCI levels, Pharmacyte Biotech Inc. (PMCB) currently has a 14-day Commodity Channel Index (CCI) of 35.14. Investors and traders may use this indicator to help spot price reversals, price extremes, and the strength of a trend. Many investors will use the CCI in conjunction with other indicators when evaluating a trade. The CCI may be used to spot if a stock is entering overbought (+100) and oversold (-100) territory.
Pharmacyte Biotech Inc. (PMCB’s current 14-day RSI is at 66.79, the 7-day is 63.54, and the 3-day is seen at 62.8. The RSI, or Relative Strength Index is a popular oscillating indicator among traders and investors. The RSI operates in a range-bound area with values between 0 and 100. Many traders keep an eye on the 30 and 70 marks on the RSI scale. A move above 70 is widely considered to show the stock as overbought, and a move below 30 would indicate that the stock may be oversold. Traders may use these levels to help identify stock price reversals.
What does the level 2 look like? OTCmarkets isn't loading
Hope everyone had a good holiday.
I gotta get ready and drive to Indiana for the holiday so I'll see you guys sometime on Monday.
What does a U mean in level 2? Every morning I look and see ETRF as a U.
Ouch those are expensive trades
Just checked out etrade, looks like you need to make 150+ trades a quarter for the 7.99$ rate, otherwise it's 9.99 a trade. I didn't see any fine print either.
I was looking at fidelity they offer 7.95 a trade, but I realized they also have a sell fee of .01 to .03 per 1000$ of principal.
Haha exactly what I did, sold off VLO and bought PMCB from the MM CDEL.
173,606.000 $0.11
Have a good one i'll be heading out tomorrow until after the weekend
We'll be partying on the plane and never make it there.
Can you do that even if you haven't had income in 2017 yet? I'm sure to make 5500 in 2017 just won't start making money until probably April.
Haha yep I'll just keep the gold teeth on the side, happy with my pearly whites :)
Saw he did some yesterday but not on PMCB.
Haha I did basically the same thing, just about a quarter of what you made though :)
They let you margin penny stocks? Fidelity won't let me margin them :(
Very nice pickup. Wish I could grab more
There are also those people that could take a profit to offset losses they took on other investments. It's someone's personal choice. Not everyone is long on PMCB like some of us and they might want to take a quick few bucks instead of retiring.
yep it's called a wash sale. If you take a loss then you have to wait 30 days before you can buy it back or any other stock that is closely related to the sold stock otherwise it's considered a wash sale and you can't deduct the loss from taxes.
Happened to me when I sold a stock for a profit this year and a partial share I got from dividends was a 6 cents loss. So I can't claim that 6 cents.
I posted some translations in the comments. I think you can hover over the comment boxes near the German phrases. I skipped some sections and tried to highlight the more relevant stuff.
Skipped over stuff like what is diabetes and such.
Science meets industry 2016
This is the December 15th, 2016 presentation by Lilli Brandtner in German, easily translatable. Of course the information she presents orally isn't shown here only what is on the PowerPoint slides, so not the whole presentation but a visual one.
https://www.dropbox.com/s/13i3i7povcxwh2j/BRANDTNER_BioLAGO%20Wissenschaft%20trifft%20Wirtschaft%202016.pdf?dl=0
Okay I just realized I had dropbox and could upload it and share a link. Hopefully dropbox doesn't limit how many users can view it.
Ya it's not posted anywhere. I submitted a request for it and had to answer questions and wait until the weekend was over to get it.
I obtained it through email, I don't have a link. If you pm me your email address I can send it to you.
Ya I didn't realize he was traveling or I wouldn't bug him.
Okay sounds good :)
Pete can you post the presentation here from Thursday. I'm not sure how to do it myself.
PistolPete just posted this elsewhere. Maybe he's having trouble getting on ihub.
http://yankeeanalysts.com/2016/12/19/rsi-review-on-shares-of-pharmacyte-biotech-inc-pmcb/
Level 2 looks like .1459
MPID
Ask Price
Size
Date/Time
NITE 0.1458 32000 11:16
WDCO 0.1458 5000 10:58
CANT 0.1459 20000 11:09
CDEL 0.1459 9300 11:13
CSTI 0.1459 5000 11:08
ETRF 0.1459 5000 11:18
DLNY 0.148 5000 09:17
How do you reduce the float, I always see it at 849m shares. When we buy shares it doesn't go down does it? or are we buying so few shares that we don't really see the number change?
Look at my posts a few hours ago, I post a translation of the presentation. I emailed the presentation to pistolpete to upload for us since I wasn't sure how to upload a file. It's in German btw
0.145 / 0.148 (5000 x 15000)
http://www.otcmarkets.com/stock/PMCB/quote
I can give the translation from google translate, but I'm hoping to get the original presentation posted here by pistolpete. Then you can follow along.
Of course I don't know how she explained things other than what was in the PowerPoint presentation.
Is diabetes curable in the future?
Diabetes type 1 therapy by transplantation
encapsulated insulin-producing cells
Dr. Eva Maria (Lilli) Brandtner
VIVIT Vorarlberg
BioLAGO science meets industry
Constance, 15th December 2016
What is type 1 diabetes?
healthy type 1 diabetes
Immune cells
destroy insulin
producing
Beta cells
Can pancreas
No insulin
produce
more glucose in your blood goes to insulin
the cells
Pancreas
produces
Insulin
Glucose
joshya/Shutterstock.com
Picture dwarf - Fotolia.com
High blood pressure, sexual disorders, etc.
SYMPTOMS
• Frequent urination
• Strong thirst
• Weight loss
• Malaise, fatigue, and weakness
• Blurred vision
• Loss of consciousness
unknown
< 2 2-5 5-10 10-25 > 25
Around the world (by 2015):
415 million adults
500 000 children
5-10% OF T1D
3% global increase of T1D Neuerkrankugen per year
International Diabetes Federation
T1D new disease per 100,000 children per year
International Diabetes Federation
Who has diabetes?
Is diabetes curable?
Betazell transplantation
• Treatment by injection of insulin / insulin pumps
• Advanced cases of type 2 diabetes
• Healing: pancreatic and Betazell transplantation
• today: only about 1000 patients worldwide transplanted
• Shortage of donor organs:
1 transplant/625 T1DM patients. 2-4 Pankreata/patient
• Serious risks and side effects of immune supprimierenden
Medications for graft rejection
What can cell encapsulation?
Sugar
Insulin
Immune
Cells
• allows the transplant of alien cells without immune supprimierende
Medicines
• Diameter: 0.7 mm
• contains up to 10,000 cells
Cellulose sulphate capsules
• electron microscopic images
• on cotton basis
• can be frozen (including cells)
confidential data
Does it work?
Blood sugar levels of animals under the following conditions:
(?) diabetic control group (n = 5).
(?) animals with graft, Explantation of capsules on day 15 (n = 5)
(?) Explantation of capsules at day 45 (n = 5)
(?) Explantation of capsules at day 150 (n = 5)
Time (days)
Blood glucose (mg/dl)
Try encapsulated pig beta cells in diabetic rats
All transplanted animals had normal blood sugar levels during the entire
Test duration (150 days) or until the grafts were removed.
What kind of cells?
MELL-CELLS UTS Australia
• Liver cells: robust
• genetically modified so that they make insulin,
Save and increased blood sugar levels
unlock
pmol insulin/10 6 cells
Glucose (mmol/l)
Insulin secretion
(relative to the level before the stimulation)
Group number
Start the stimulation
(20 mM glucose)
At the end of the
Stimulation
Prof. Dr. Walter Günzburg
Dr Brian Salmons
Dr. John Dangerfield
Dr. Kenneth L. Waggoner
Dr. Gerald W. Crabtree
Dr. Eva Maria Brandtner
Prof. Dr. Matt Löhr
Prof. Axel
Kornerup Hansen
Prof. Dr. Ann Simpson
Dr. Brenton Hadi
Dr. Constantine Konstantoulas
Prof. Dr. Thomas Stratmann
Prof. Dr. Rüdiger Wanke
Prof. Dr. Eckhard Wolf
Dr. Andreas Blutke
This research was supported by a
Marie Curie FP7 integration Grant as part of the 7th European framework programme
Guys I got something for us (though) in German. I have asked PistolPete if he can upload it. :)
morning we are back